Headlines about Kite Pharma (NASDAQ:KITE) have trended negative recently, AlphaOne Sentiment Analysis reports. The research firm, a service of Accern, identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kite Pharma earned a news sentiment score of -0.29 on AlphaOne’s scale. AlphaOne also gave media headlines about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted AlphaOne’s analysis:
- Insider Selling: Kite Pharma, Inc. (KITE) Director Sells 20,450 Shares of Stock (americanbankingnews.com)
- Insider Selling: Kite Pharma, Inc. (KITE) Director Sells 20,000 Shares of Stock (americanbankingnews.com)
- Kite Pharma Sentiment Improves on Better Stock Potential (emfizz.com)
- Institutional Investors Are Betting On Kite Pharma (NASDAQ:KITE) (fumbleboard.com)
- Kite Pharma (NASDAQ:KITE) 2016 Q4 Sentiment Report (healthcaremenu.net)
Several equities analysts have recently commented on KITE shares. FBR & Co restated an “outperform” rating and issued a $91.00 target price (up from $90.00) on shares of Kite Pharma in a research report on Tuesday, May 9th. Jefferies Group LLC restated a “buy” rating and issued a $101.00 target price (up from $82.00) on shares of Kite Pharma in a research report on Thursday, March 16th. Vetr cut shares of Kite Pharma from a “sell” rating to a “strong sell” rating and set a $70.37 target price for the company. in a research report on Thursday, March 9th. Wells Fargo & Company started coverage on shares of Kite Pharma in a research report on Wednesday, February 22nd. They issued a “market perform” rating for the company. Finally, HC Wainwright restated a “buy” rating and issued a $85.00 target price (up from $78.00) on shares of Kite Pharma in a research report on Wednesday, February 22nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Kite Pharma presently has an average rating of “Buy” and an average price target of $83.13.
Kite Pharma (NASDAQ KITE) traded up 0.14% during midday trading on Friday, reaching $87.85. 1,237,834 shares of the company’s stock were exchanged. The stock’s market cap is $4.97 billion. Kite Pharma has a 12 month low of $39.82 and a 12 month high of $91.76. The firm has a 50 day moving average of $78.04 and a 200-day moving average of $66.04.
Kite Pharma (NASDAQ:KITE) last posted its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.68) by $0.06. The business had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $8.85 million. Kite Pharma had a negative return on equity of 55.80% and a negative net margin of 1,166.54%. The company’s revenue was up 92.2% compared to the same quarter last year. During the same period last year, the business posted ($0.60) earnings per share. On average, equities research analysts predict that Kite Pharma will post ($8.05) earnings per share for the current year.
In other news, Director Farah Champsi sold 20,450 shares of the firm’s stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $89.79, for a total value of $1,836,205.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Cynthia M. Butitta sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 27th. The stock was sold at an average price of $77.67, for a total transaction of $776,700.00. Following the completion of the transaction, the chief operating officer now owns 127,795 shares in the company, valued at approximately $9,925,837.65. The disclosure for this sale can be found here. Over the last three months, insiders have acquired 70,450 shares of company stock worth $4,863,126 and have sold 448,908 shares worth $37,369,692. Company insiders own 20.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Kite Pharma (KITE) Earning Critical News Coverage, Analysis Finds” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2017/06/16/kite-pharma-kite-receives-media-sentiment-score-of-0-29-updated-updated-updated.html.
About Kite Pharma
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.